Pharmacological inhibition of the SHH pathway results in an attenuation of fibrosis in a variety of in vivo models, namely unilateral ureteral obstruction (UUO) [67], systemic sclerosis [68] and liver cirrhosis [66], [69], [70], although others did not report improvements [71], [72]. This evidence concerns the gene SHH and systemic sclerosis.